# EDGAR Filing Document

**Accession Number:** 0001673776
**File Stem:** 0000879169-25-000085
**Filing Date:** 2025-7
**Character Count:** 7644
**Document Hash:** e0ff0bb239a2e22341ca3349467f9976
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000879169-25-000085.hdr.sgml**: 20250716

**ACCESSION NUMBER**: 0000879169-25-000085

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250714

**FILED AS OF DATE**: 20250716

**DATE AS OF CHANGE**: 20250716

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stein Steven H
- **CENTRAL INDEX KEY:** 0001673776

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12400
- **FILM NUMBER:** 251127432

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stein Steven H<br><sub>(Last) (First) (Middle)</sub><br>1801 AUGUSTINE CUT-OFF<br><sub>(Street)</sub><br>WILMINGTON, DE 19803<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP & Chief Medical Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>INCYTE CORP [ INCY ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-07-14 |  | S |  | 14952 | D | $68.47 | 97466 | D |  |
| Common Stock | 2025-07-14 |  | F |  | 1555<sup>(1)</sup> | D | $69.98 | 95911 | D |  |
| Common Stock | 2025-07-15 |  | F |  | 1596<sup>(1)</sup> | D | $68.25 | 94315 | D |  |
| Common Stock | 2025-07-15 |  | A |  | 12277<sup>(2)</sup> | A | $0 | 106592<sup>(3)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Performance Shares | <sup>(4)</sup> | 2025-07-15 |  | A |  | 30692 |  | <sup>(4)</sup> | 2028-07-15 | Common Stock | 30692 | $0 | 30692 | D |  |
| Employee Stock Option (right to buy) | $68.25 | 2025-07-15 |  | A |  | 27629 |  | <sup>(5)</sup> | 2035-07-14 | Common Stock | 27629 | $0 | 27629 | D |  |

---

### Footnotes:

(1) Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

(2) Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

(3) Including the July 15, 2025 grant, this includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

(4) Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

(5) The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

**Signature:** /s/ Elizabeth Feeney, Attorney-In-Fact  
**Date:** 2025-07-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**